Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Mitchell

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
Molecular Diagnosis & Therapy|November 11, 2025
Clinical Utility of an RNA-based Gene Fusion Assay in Sarcoma for Diagnosis and Management: Experience in an Australian LaboratoryAdel Shahnam, Catherine Mitchell, Christopher R McEvoy, et al.
Heliyon|January 15, 2025
A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent <i>RAS</i> mutant colorectal cancerSara Roth, Kasmira Claire Wilson, Robert George Ramsay, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 3, 2020
A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumorsChristopher R McEvoy, Holly Holliday, Niko Thio, et al.
Cell Metabolism|October 3, 2006
Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistanceMaura Agostini, Erik Schoenmakers, Catherine Mitchell, et al.
Pigment Cell & Melanoma Research|February 6, 2014
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesRichard J Young, Kelly Waldeck, Claire Martin, et al.
Virchows Archiv : an International Journal of Pathology|April 3, 2024
Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology AssessmentsJosef Rüschoff, George Kumar, Sunil Badve, et al.
Genome Medicine|October 7, 2025
Pathologist-initiated whole genome and transcriptome sequencing demonstrates diagnostic utility in resolving difficult-to-diagnose tumorsJoseph H A Vissers, Catherine Mitchell, Owen W J Prall, et al.
Journal for Immunotherapy of Cancer|June 28, 2022
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genesAnna Sofia Trigos, Anupama Pasam, Patricia Banks, et al.
Iscience|November 19, 2019
E6AP Promotes a Metastatic Phenotype in Prostate CancerCristina Gamell, Ivona Bandilovska, Twishi Gulati, et al.
European Urology|October 27, 2023
Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 StudyRenu S Eapen, James P Buteau, Price Jackson, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Molecular Diagnosis & Therapy|November 11, 2025
Clinical Utility of an RNA-based Gene Fusion Assay in Sarcoma for Diagnosis and Management: Experience in an Australian LaboratoryAdel Shahnam, Catherine Mitchell, Christopher R McEvoy, et al.
Heliyon|January 15, 2025
A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent <i>RAS</i> mutant colorectal cancerSara Roth, Kasmira Claire Wilson, Robert George Ramsay, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 3, 2020
A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumorsChristopher R McEvoy, Holly Holliday, Niko Thio, et al.
Cell Metabolism|October 3, 2006
Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistanceMaura Agostini, Erik Schoenmakers, Catherine Mitchell, et al.
Pigment Cell & Melanoma Research|February 6, 2014
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesRichard J Young, Kelly Waldeck, Claire Martin, et al.
Virchows Archiv : an International Journal of Pathology|April 3, 2024
Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology AssessmentsJosef Rüschoff, George Kumar, Sunil Badve, et al.
Genome Medicine|October 7, 2025
Pathologist-initiated whole genome and transcriptome sequencing demonstrates diagnostic utility in resolving difficult-to-diagnose tumorsJoseph H A Vissers, Catherine Mitchell, Owen W J Prall, et al.
Journal for Immunotherapy of Cancer|June 28, 2022
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genesAnna Sofia Trigos, Anupama Pasam, Patricia Banks, et al.
Iscience|November 19, 2019
E6AP Promotes a Metastatic Phenotype in Prostate CancerCristina Gamell, Ivona Bandilovska, Twishi Gulati, et al.
European Urology|October 27, 2023
Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 StudyRenu S Eapen, James P Buteau, Price Jackson, et al.
Pageof 12